Plain-English translation of NCT04014530 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether pembrolizumab—a medication that helps your immune system recognize and attack cancer cells—works better when combined with ataluren, a drug designed to create additional targets for your immune system to recognize. The study focuses on advanced colorectal and endometrial cancers, particularly those with certain genetic characteristics. Researchers believe that combining these two medications may help your body's natural defenses fight the cancer more effectively.
Many cancers trick your immune system into ignoring them by blocking important signals. While the medication has shown promise in some patients, researchers want to see if combining it with this treatment could create more opportunities for the immune system to detect and destroy cancer cells.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive intravenous infusions of one medication every three weeks and take the other medication orally at doses determined to be safe in earlier participants. You will have blood tests and imaging scans regularly to monitor how the cancer responds and to watch for side effects. You will also have tumor biopsies (tissue samples taken with a needle or small procedure) before starting treatment and again during or after treatment to help researchers understand how the medication is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Netherlands